RYAH Medtech
Inc. Ships Devices for Use in Pilot Study with CLINN Medical
Center
NEW
YORK,
May 25,
2021 -- InvestorsHub NewsWire
-- RYAH Group,
Inc.'s (CSE:RYAH) ("RYAH" or the "Company") wholly
owned subsidiary,
RYAH Medtech Inc. ("RYAH Medtech"), announces it has
completed initial
shipment of its proprietary Smart Dose-Measuring inhalers for use
in a pilot study conducted by CLINN medical center in Milan, Italy.
CLINN, the first and only cannabis-specialized clinic in
Italy, named the best cannabis clinic in
Europe by
CanEx, is
launching an observation study using RYAH devices in order to
collect accurate patient feedback on consumption of
cannabis strains
available on the Italian market (Bedrocan from the Netherlands, Aurora
from Canada and FM2 from Italy's national military
production).
With 30% growth over the last year, Italy
remains the second-largest market in Europe with
more than 20,000
patients, which makes it a priority
market for RYAH Group, Inc. Italy has also
been a strong market for CBD products, boasting a national market
of €786 million - 11% of Italians
surveyed by New Frontier Data had purchased
CBD products - and huge growth projections for a CBD market
potentially worth €1.29 billion by 2025.
"We are
delighted to bring RYAH Medtech's Smart-Inhaler
to the CLINN network and support
CLINN in integrating their data
collection software. The combination of
dose-control and data analytics with CLINN's extensive acumen in
plant-based medicine research will set a new standard in
cannabis therapies in
Italy," says Andrea Ferrari, RYAH's
European Business Development Manager.
Dr. Annunziata
Lombardi, regulatory and pharmaceutical counselor for
RYAH in Europe, added, "This joint effort with CLINN
will also help RYAH in collecting valuable
feedback from patients to constantly improve the product, as well as
obtaining
feedback from the Italian pharmacists to
validate
and launch
innovative cartridge filling models to be successfully
rolled out to all
pharmacies in Europe."
About RYAH
Medtech, Inc.
RYAH Medtech Inc.
("RYAH") is a connected device and
big data and technology company focused on valuable predictive
analysis in the global medical plant and nutraceutical intake
industry. Its robust artificial intelligence platform aggregates
and correlates HIPAA-compliant patient data, which is intended to help
doctors and patients personalize plant-based treatments to better
predict treatment outcomes. The data collection is relevant for
clinics, doctors, dispensaries and pharmaceutical companies
and licensed processors (LPs) to monitor
and manage formulation effects on patients and demographics. With a
strong IP portfolio, RYAH gathers deep and insightful data on the
complete patient session and formulation life cycle.
Forward-Looking Statements
Certain
statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may,"
"would,"
"could,"
"should,"
"potential,"
"will,"
"seek,"
"intend,"
"plan,"
"anticipate,"
"believe,"
"estimate,"
"expect" and similar expressions as they relate to the Company are
intended to identify forward-looking information. All statements
other than statements of historical fact may be forward-looking
information. Forward-looking statements in this news release
include statements relating to RYAH Medtech's intention and ability
to complete the development and distribution of RYAH Smart Inhalers
on the terms and conditions set out in the Agreement; the potential
effects of the Agreement and partnership with DelleD SAS on the
business of RYAH; and statements regarding the sale of RYAH's
products. While RYAH considers these assumptions to be reasonable,
based on information currently available, they may prove to be
incorrect. Readers are cautioned not to place undue reliance on
forward-looking statements.
Such
statements reflect the Company's current views and intentions with
respect to future events and current information available to the
Company and are subject to certain risks, uncertainties and
assumptions. Many factors could cause the actual results,
performance or achievements that may be expressed or implied by
such forward-looking information to vary from those described
herein should one or more of these risks or uncertainties
materialize. These factors include, without limitation: the general
business and economic conditions in the regions in which the
Company operates; the ability of the Company to execute on key
priorities, including the successful completion of acquisitions,
business retention and strategic plans and to attract, develop and
retain key executives; difficulty integrating newly acquired
businesses; the
benefits of RYAH's user-generated, HIPAA-compliant data; the
success of its launch in Europe; RYAH's plan to roll
out
several other clinical delivery mechanisms; the results users may
receive from using RYAH products; the ability to implement business
strategies and pursue business opportunities; disruptions in or
attacks (including cyberattacks)
on the Company's information technology, internet, network access
or other voice or data communications systems or services; the
evolution of various types of fraud or other criminal behavior to
which the Company is exposed; the failure of third parties to
comply with their obligations to the Company or its affiliates; the
impact of new and changes to, or application of, current laws and
regulations; legal and regulatory risks inherent in the cannabis
industry; risks relating to the regulatory landscape in certain
countries and enforcement related to cannabis, including political
risks; risks relating to anti-money-laundering
laws and regulation; other governmental and environmental
regulation; public opinion and perception of the cannabis industry;
risks related to proprietary intellectual property and potential
infringement by third parties; risks inherent in an agricultural
business; risks associated to cannabis products manufactured for
human consumption including potential product recalls; a novel
business model; granting of permits and licenses in a highly
regulated business; the overall difficult litigation environment,
including in the United States; increased competition; changes in
foreign currency rates; increased funding costs and market
volatility due to market illiquidity and competition for funding;
the availability of funds and resources to pursue operations;
critical accounting estimates and changes to accounting standards,
policies and methods used by the Company; the occurrence of natural
and unnatural catastrophic events and claims resulting from such
events; and the risk associated with a business in the cannabis
industry. Should any
factor affect the Company in an unexpected manner, or should
assumptions underlying the forward-looking information prove
incorrect, the actual results or events may differ materially from
the results or events predicted. Any such forward-looking
information is expressly qualified in its entirety by this
cautionary statement. Moreover, the Company does not assume
responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and the Company undertakes no obligation to publicly update
or revise any forward-looking information, other than as required
by applicable law.
RYAH
Medtech Inc Contacts:
Sofiya Kleshchuk
Client Relations
+1 917 210
0543
Invest@ryahgroup.com
Gregory Wagner, CEO
917 210 0543
Info@ryah.com
Corporate Communications:
InvestorBrandNetwork
(IBN)
Los Angeles,
California
www.InvestorBrandNetwork.com
310.299.1717
Office
Editor@InvestorBrandNetwork.com
